News Column

Studies from University of Miami Miller School of Medicine Update Current Data on Gene Therapy

June 3, 2014



By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Biotechnology have been published. According to news reporting out of Miami, Florida, by NewsRx editors, research stated, "The urokinase receptor (uPAR) is a clinically relevant target for novel biological therapies. We have previously rescued oncolytic measles viruses fully retargeted against human (MV-h-uPA) or murine (MV-m-uPA) uPAR."

Our news journalists obtained a quote from the research from the University of Miami Miller School of Medicine, "Here, we investigated the in vivo effects of systemic administration of MV-m-uPA in immunocompetent cancer models. MV-m-uPA induced in vitro cytotoxicity and replicated in a receptor-dependent manner in murine mammary (4T1) and colon (MC-38 and CT-26) cancer cells. Intravenous administration of MV-m-uPA to 4T1 tumor-bearing mice was not associated with significant clinical or laboratory toxicity. Higher MV-N RNA copy numbers were detected in primary tumors, and viable viral particles were recovered from tumor-bearing tissues only. Non-tumor-bearing organs did not show histological signs of viral-induced toxicity. Serum anti-MV antibodies were detected at day 14 of treatment. Immunohistochemistry and immunofluorescence studies confirmed successful tumor targeting and demonstrated enhanced MV-m-uPA-induced tumor cell apoptosis in treated compared with control mice. Significant antitumor effects and prolonged survival were observed after systemic administration of MV-m-uPA in colon (CT-26) and mammary (4T1) cancer models."

According to the news editors, the research concluded: "The above results show safety and feasibility of uPAR targeting by an oncolytic virus, and confirm significant antitumor effects in highly aggressive syngeneic immunocompetent cancer models."

For more information on this research see: In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models. Gene Therapy, 2014;21(3):289-97. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)

Our news journalists report that additional information may be obtained by contacting Y. Jing, Dept. of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, United States. Additional authors for this research include J. Zaias, R. Duncan, S.J. Russell and J.R Merchan (see also Biotechnology).

Keywords for this news article include: Biotechnology, Miami, Cancer, Florida, Viruses, Oncology, Virology, United States, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters